DUBLIN, Oct. 13, 2021 /PRNewswire/ -- The "Global Drug Discovery and Early Development Outsourcing Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
Post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market are presented in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions.
The report identifies the evolving competitive landscape and initiatives taken by key contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) to adapt to the growing needs of pharmaceutical and biotechnology sponsors.
The drug discovery and early development outsourcing market was worth $19.65 billion in 2020 and is estimated to grow at a compound annual growth rate of 6.4% up to 2026, with North America continuing to lead the market.
In terms of overall R&D expenditure, the contribution of large pharmaceutical companies is steadily declining due to their focus on leaner portfolios. In contrast, the contribution of emerging biotechnology companies to drug development has grown more than 80% since 2018. Pharmaceutical companies are directing their R&D spending mainly toward strengthening their oncology portfolio and increasing year-on-year acquisitions of clinical-stage biopharmaceutical companies focusing on oncology therapy, suggesting both the potential of new technologies and promising returns on investment for these assets.
Leading CROs and CDMOs are also focused on oncology, with anticancer drugs reportedly contributing the highest to the drug development pipeline in 2020. COVID-19-related drug discovery and early development research is projected to slow down in 2022 as most projects would have advanced to the clinical research stage by then. When pandemic-related restrictions are lifted, a surge in outsourcing for the next two years is expected as companies resume their non-COVID-19 drug discovery programs that were stalled during the pandemic.
In the United States and Europe, testing service providers with best-in-class good laboratory practices (GLP) and good track records are the preferred partner for completing investigational new drugs-enabling studies. Global CROs may have in-house capabilities, but pharmaceutical companies still prefer independent validation from specialists to minimize the risk of failure early on in the development life cycle before moving toward regulatory filing.
Key industry participants are positioning themselves to be end-to-end integrated service providers for pharmaceutical and biotechnology sponsors.
The growing demand for end-to-end integrated drug discovery and development support is closing the gap that distinguishes a CRO from a CDMO. The promise of artificial intelligence in drug discovery, along with novel approaches to target "undruggable" RNA, is set to drive small molecule drug discovery and outsourcing while the growth in biologics is expected to boost the need for better disease models and advanced in vivo pharmacology capabilities.
Exploring novel expression systems to support the urgent needs of infectious disease management is also forecast to gain momentum especially as the industry favors single-use reactors for future biotherapeutics.
Key Topics Covered
1. Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8
- The Impact of the Top Three Strategic Imperatives on the Global Drug Discovery and Early Development Outsourcing Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
2. Market Overview and Dynamics - R&D Landscape
- Pharmaceutical Market
- Pharmaceutical Market - Top 20 Pharma Companies
- Pharmaceutical Market - Global R&D Expenditure
- Top 20 Pharma Companies' R&D Expenditure
- Global Clinical Development Expenditure by Therapy Area
- Global Drug Development Pipeline by Clinical Phase
- Drug Development Pipeline by Clinical Phase - North America
- Drug Development Pipeline by Clinical Phase - Europe
- Venture Capital Landscape by Clinical Phase
- M&A Landscape
3. Growth Opportunity Analysis
- Scope of Analysis
- Key Growth Metrics
- Key Competitors
- Key Services
- Growth Drivers for the Drug Discovery and Early Development Outsourcing Market
- Growth Restraints for the Drug Discovery and Early Development Outsourcing Market
- Market Segmentation by Service Type
- Revenue Forecast
- Revenue Forecast by Service Type
- Revenue Forecast Analysis
- Key Drivers by Region
- Key Trends Analysis by Therapy
- Key Trends Analysis by Service
- Competitive Environment
- Competitive Landscape
- Key Participants' Capability Profile
- Future Outlook for Key CROs
- Future Outlook for Key CDMOs
- Evolution of Drug Discovery and Early Development Value Chain
4. Growth Opportunity Universe
- Growth Opportunity 1 - AI in Early Drug Discovery (Lead Selection and Optimization)
- Growth Opportunity 2 - High-throughput Screening for RNA-targeting Small Molecule Therapy
- Growth Opportunity 3 - Ex vivo/In vivo Pharmacology Services in APAC
- Growth Opportunity 4 - Emerging Expression Platforms for Next-generation Biologics
5. Next Steps
- Your Next Steps
6. List of Exhibits
For more information about this report visit https://www.researchandmarkets.com/r/1u5dhe
Research and Markets Laura Wood, Senior Manager firstname.lastname@example.org For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
View original content: https://www.prnewswire.com/news-releases/drug-discovery-and-early-development-outsourcing-markets-to-2026---rd-efforts-market-trends-key-participants-drivers--restraints-of-market-adoption-recent-mas-301399647.html
SOURCE Research and Markets